Recognizing Progress in an Unprecedented Year

Thursday, December 3, 2020 | Virtual

California Life Sciences AssociationCalifornia Life Sciences Association

Outstanding Product, Therapeutic


In June 2019, the FDA granted accelerated approval to Polivy, in combination with Rituxan, for the treatment of relapsed or refractory diffuse Large B-cell lymphoma, for patients who have received at least two prior therapies.  Despite meaningful progress in the treatment of diffuse large B-cell lymphoma, treatment options for these patients have been very limited when the disease is refractory to or recurrent after multiple regimens.  Polivy is a first-in-class anti-CD79b antibody-drug conjugate which targets a protein expressed in the majority of B-cells.  The approval of Polivy provides a novel treatment option for patients with this aggressive disease.  It is estimated that nearly 25,000 new cases of diffuse Large B-cell lymphoma will be diagnosed this year. 

Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit